Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Ver. Summary Created by Modification Content Size Created at Operation
1 + 1128 word(s) 1128 2021-10-19 05:14:32 |
2 format correct + 94 word(s) 1222 2021-11-17 10:27:01 |

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Edinoff, A.; Cornett, E.; Kaye, A.; Kaye, A.D. Pharmacologic and Clinical Considerations of Nalmefene. Encyclopedia. Available online: (accessed on 03 December 2023).
Edinoff A, Cornett E, Kaye A, Kaye AD. Pharmacologic and Clinical Considerations of Nalmefene. Encyclopedia. Available at: Accessed December 03, 2023.
Edinoff, Amber, Elyse Cornett, Adam Kaye, Alan David Kaye. "Pharmacologic and Clinical Considerations of Nalmefene" Encyclopedia, (accessed December 03, 2023).
Edinoff, A., Cornett, E., Kaye, A., & Kaye, A.D.(2021, November 15). Pharmacologic and Clinical Considerations of Nalmefene. In Encyclopedia.
Edinoff, Amber, et al. "Pharmacologic and Clinical Considerations of Nalmefene." Encyclopedia. Web. 15 November, 2021.
Pharmacologic and Clinical Considerations of Nalmefene

Nalmefene is a pure opioid antagonist structurally similar to naltrexone that can serve as an alternative antidote for reversing respiratory depression associated with acute opioid overdose. Nalmefene is also known as 6-methylene naltrexone. Its main features of interest are its prolonged duration of action that surpasses most opioids and its ability to serve as an antidote for acute opioid overdose.

nalmefene opioid overdose naloxone harm reduction antidote

1. Introduction

The primary drug for combatting acute opioid overdose has been naloxone. In overdose situations and for clinical uses, the respiratory depression and sedative effects of opioids can occur for several hours after administration [1][2]. This requires more hours of patient monitoring for signs of respiratory depression and potential repeated administration of naloxone, as the duration of action (DOA) of naloxone is generally 64 min [3]. This brings light to the pertinent issue associated with naloxone: its DOA is less than that of most frequently abused opioids [4][5].

This central issue with naloxone has led much research toward an alternative opioid antagonist with a longer DOA. Nalmefene is a pure opioid antagonist structurally similar to naltrexone that can serve as an alternative antidote for reversing respiratory depression associated with acute opioid overdose. The key feature of nalmefene is its increased DOA being several hours longer than naloxone and its ability to serve as an antidote during acute opioid overdose, unlike naltrexone. This can help patients be discharged earlier and decrease nursing observation by 2–4 h [3][4]. An alternative opioid overdose antidote on the market is further beneficial with the marked rise in opioid overdose deaths.

On 13 March 2019, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Purdue Pharma L.P.’s Nalmefene HCl injections to treat known or suspected opioid overdose [6]. Reasons for Fast Track designation include the marked rise in opioid overdoses in the U.S. and the subsequent need for more reversal agents of similar or better efficacy than naloxone.

Though nalmefene has displayed efficacy in treating alcohol dependence in humans [7], this review will focus on nalmefene’s implications with opioid use disorder (OUD) and opioid overdose. This study was designed to analyze the efficacy and practicality of nalmefene treatment in OUD and suspected opioid overdose cases by reviewing the history of nalmefene research in human subjects.

2. Nalmefene

Nalmefene HCl is a pure opioid receptor antagonist and is considered the longest-acting parenteral opioid antagonist commercially available for OUD and opioid overdose. It is a white crystalline substance, and its chemical name is 17-(cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinan-3,14-diol, hydrochloride salt. It can be used to prevent or counter the various consequences of opioid overdose or post-surgery opioid effects, such as respiratory depression and sedation. Desirable outcomes of nalmefene administration include alleviation of respiratory depression, nerve center depression, and hypotension associated with prolonged opioid receptor activation [8]. A pill form of nalmefene is manufactured in Japan, England, and other European countries under the brand name of Selincro ® for the treatment of alcohol dependence in decreasing alcohol intake [9].

In 1995, nalmefene HCl was granted approval by the U.S. FDA to treat known or suspected opioid overdose and was sold under the brand name Revex ® . Nalmefene can be administered intravenously (IV), intramuscularly (IM), or subcutaneously (SC). Nalmefene is currently sold in two doses, with the concentration being dependent on postoperative or overdose use. Nalmefene is available in a blue-labeled ampul containing 1 mL at a concentration of 100 µg/mL for postoperative use. For opioid overdose reversal, nalmefene is available in a green-labeled ampul containing 2 mL at a 1 mg/mL concentration, being ten times more concentrated than the postoperative formulation [10]. An initial dose of 0.5 mg/70 kg for opioid overdose reversal is recommended and can be followed up 2–5 min with a 1.0 mg/70 kg dose [10]. Intravenously administration of nalmefene generally takes 2 min for initiation of opioid reversal [10]. If nalmefene is administered via intramuscular (IM) or subcutaneous (SC) routes, it may take 5–15 min for a 1 mg dose to be effective [8].

Nalmefene is well tolerated in human subjects for up to 24 mg of IV doses [11]. In most studies, its side effects were transient, relatively mild, and similar to naloxone’s side effects. The main side effects for both are nausea, vomiting, tachycardia, hypertension, pain, fever, and dizziness [8]. However, it can produce acute withdrawal symptoms in those physically dependent on opioids [8]. Furthermore, nalmefene is only known to have net antagonistic effects on opioid receptors and is not considered abuse potential nor cause physical dependence [12].

Nalmefene also has a higher potency for opioid receptors than naloxone. Its potency is 4 times higher than naloxone at MOR and slightly more potent at KOR [13]. Nalmefene also has a longer elimination half-life, ranging from 8 to 11 h, and a longer duration of action of 1–4 h [13]. The longer duration of action is also associated with the medication’s slow dissociation from the opioid receptor [13].

3. Nalmefene vs. Naloxone

Nalmefene and naltrexone are pure opioid antagonists that block receptor activity of the mu, kappa, and delta sub receptors in the CNS [14]. Nalmefene is a methylene analog of naltrexone that was originally approved in 1995 as a more potent analog. Nalmefene is has a slightly slower onset of action when given IV (5–15 min compared to 1–2 min with naloxone), equipotent binding power compared to naloxone, a longer DOA, and a much longer plasma half-life (8–11 h compared to 80 min with naloxone) [15]. Both naloxone and nalmefene are indicated in acute opioid intoxication characterized by respiratory depression, coma, or hypotension. Off-label uses for both agents include clonidine, benzodiazepine, ethanol, or valproic acid overdoses [16]. Overall, both agents are useful for acute opioid withdrawal despite a longer DOA, similar potency, and a longer onset of action is seen in nalmefene compared to naloxone.

4. Naltrexone

Naltrexone is a pure opioid antagonist and is used for the reduction of cravings and consumption of both opioids and alcohol. Of note, naltrexone is not indicated for acute opioid intoxication. In fact, naltrexone has been implicated in acute opioid overdose deaths as it can lower the patient’s tolerance to opioids. These overdoses happen after a period of abstinence and discontinuation of naltrexone [17]. This makes them more susceptible to overdose with a smaller amount of opioids used than in the past.

Naltrexone comes in an oral or a long-acting injectable form, called vivitrol. Historically, patients would have to show that oral naltrexone was tolerable without an increase in liver function enzymes prior to starting the injectable form. It is because of this that naltrexone has not been useful in an acute overdose situations since oral medicine cannot be given to someone who is unconscious. The injectable form comes with another set of barriers. Each injection is costly, at around USD 1400 a shot. It is because of this that not all pharmacies can afford to carry it, let alone have it accessible for emergency medical services. Table 1 shows a comparison of naloxone, nalmefene, and naltrexone.

Table 1. The comparison of naloxone, nalmefene, and naltrexone.
Medication Mechanism of Action Pharmacokinetics/Dynamics Uses Routes of Administration
Naloxone Antagonist of MOR Half-life: 30–120 min
Duration of Action: 1–4 h
Metabolized by: Liver
Reversal of Opioid Overdose Intranasal
Nalmefene Antagonists at MOR and DOR
Partial agoist at KOR
Half-life: 8–11 h
Duration of action: 1–4 h
Metabolized by: Liver
Reversal of Opioid Overdose Intravenous
Naltrexone Pure antagonist at the MOR, DOR, and KOR Half life: 4 h for naltrexone and 13 h for active metabolite of 6 beta-naltrexol
Duration of action:
Metabolized by: Liver
Can reduce and suppress opioid and alcohol cravings
Not used in opioid overdose


  1. Barsan, W.G.; Seger, D.; Danzl, D.F.; Ling, L.J.; Bartlett, R.; Buncher, R.; Bryan, C. Duration of antagonistic effects of nalmefene and naloxone in opiate-induced sedation for emergency department procedures. Am. J. Emerg. Med. 1989, 7, 155–161.
  2. Adams, A.P.; Pybus, D.A. Delayed respiratory depression after use of fentanyl during anaesthesia. Br. Med. J. 1978, 1, 278–279.
  3. Kaplan, J.L.; Marx, J.A.; Calabro, J.J.; Gin-Shaw, S.L.; Spiller, J.D.; Spivey, W.L.; Gaddis, G.M.; Zhao, N.; Harchelroad, J. Double-blind, randomized study of nalmefene and naloxone in emergency department patients with suspected narcotic overdose. Ann. Emerg. Med. 1999, 34, 42–50.
  4. Macmillan. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 6th ed.; Gilman, A.G., Goodman, L.S., Gilman, A., Eds.; Macmillan: New York, NY, USA, 1980; 1843p, Available online: (accessed on 21 August 2021).
  5. Evans, J.M.; Hogg, M.I.J.; Lunn, J.N.; Rosen, M. Degree and Duration of Reversal by Naloxone of Effects of Morphine in Conscious Subjects. Br. Med. J. 1974, 2, 589–591.
  6. FDA Grants Purdue Pharma’s Nalmefene HCl Injection Fast Track Designation for the Emergency Treatment of Known or Suspected Opioid Overdose. Available online: (accessed on 21 August 2021).
  7. Drobes, D.J.; Anton, R.F.; Thomas, S.E.; Voronin, K. Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol. Clin. Exp. Res. 2004, 28, 1362–1370.
  8. Federal Drug Administration. Nalmefene. Available online: (accessed on 21 August 2021).
  9. Tadori, Y. Pharmacological profile and clinical findings of nalmefene (Selincro®) for reducing alcohol consumption in patients with alcohol dependence. Nihon Yakurigaku Zasshi Folia Pharmacol. Jpn. 2020, 155, 113–119.
  10. NALMEFENE (REVEX): A Longer-Lasting Opioid Antagonist. AJN Am. J. Nurs. 1996, 96, 54–55.
  11. Dixon, R.; Gentile, J.; Hsu, H.B.; Hsiao, J.; Howes, J.; Garg, D.; Weidler, D. Nalmefene: Safety and kinetics after single and multiple oral doses of a new opioid antagonist. J. Clin. Pharmacol. 1987, 27, 233–239.
  12. Peprah, K.; Severn, M. Intranasal and Intramuscular Naloxone for Opioid Overdose in the Pre-Hospital Setting: A Review of Comparative Clinical and Cost-Effectiveness, and Guidelines ; Canadian Agency for Drugs and Technologies in Health: Ottawa, ON, Canada, 2019. Available online: (accessed on 26 November 2019).
  13. Wong, J. Chapter 208. Naloxone and Nalmefene. In Poisoning & Drug Overdose; Olson, K.R., Ed.; The McGraw-Hill Companies: New York, NY, USA, 2012.
  14. Chapter 208. Naloxone and Nalmefene|Poisoning & Drug Overdose, 6e|AccessMedicine|McGraw Hill Medical. Available online: (accessed on 22 August 2021).
  15. Colquhoun, R.; Tan, D.Y.K.; Hull, S. A comparison of oral and implant naltrexone outcomes at 12 months. J. Opioid Manag. 2005, 1, 249–256.
  16. Prevention of Opioid Overdose|NEJM. Available online: (accessed on 22 August 2021).
  17. Substance Abuse and Mental Health Services Administration. Naltrexone. Updated 15 September 2020. Available online: (accessed on 20 September 2021).
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to : , , ,
View Times: 1006
Revisions: 2 times (View History)
Update Date: 29 Mar 2022